Measurement of sodium pump inhibitor in plasma

  • Research type

    Research Study

  • Full title

    Measurement of the ’placenta-derived 370 Dalton sodium pump inhibitor’ in plasma of patients with hypertension and those undergoing intermittent haemodialysis.

  • IRAS ID

    192073

  • Contact name

    David MAKANJUOLA

  • Contact email

    david.makanjuola@esth.nhs.uk

  • Sponsor organisation

    Epsom and St Helier University Hospitals NHS Trust

  • Duration of Study in the UK

    0 years, 6 months, 1 days

  • Research summary

    It is known that extracts from human placenta and also from the blood plasma of people with an increased blood
    volume due to excess fluid contain something which impairs the action of the sodium pump which is situated in the
    membranes of body cells. Inhibition of the action of the sodium pump is also known to occur in patients with kidney
    failure and also those suffering from high blood pressure.
    Previous research has shown the presence of a substance in the blood stream of individuals with increased blood
    volume and fluid overload which has a molecular weight of 370 Daltons . This compound can be detected in the
    blood by a technique called mass spectrometry. The question has been whether this 370 Dalton substance is in
    some way implicated, perhaps through inhibiting the sodium pump, in the development of high blood pressure in
    these individuals.
    Further research had been hampered due to limits of the available technology, but recent dramatic improvements in
    the sensitivity of mass spectrometry have made it possible for us to measure substances even if only present in very
    small amounts.
    This is exciting, as it can now allow us to investigate whether the blood plasma of individuals with high blood pressure
    can be shown to have elevated concentrations of the 370 Dalton material and also to see whether the blood levels of
    this substance can be implicated in the variable blood pressures of patients undergoing haemodialysis. We may also
    be able to see whether the substance is absent in people with normal blood pressure levels.

  • REC name

    London - Bloomsbury Research Ethics Committee

  • REC reference

    16/LO/0364

  • Date of REC Opinion

    7 Mar 2016

  • REC opinion

    Further Information Favourable Opinion